Compared with the first half of 2020, LifeTech achieved an outstanding performance. The revenue was approximately RMB461.1 million, increased by approximately 68.9%, the gross profit and the net profit was recorded approximately
In the first half of 2021, the sales generated from mainland
As the performance of business segments, in the first half of 2021, the turnover contributed by the structural heart diseases business was approximately
LifeTech's peripheral vascular disease business generated the turnover of approximately
The turnover contributed by the cardiac pacing and electrophysiology business was approximately
LifeTech continuously strengthened its innovation capabilities and accelerated the R&D process of its pipeline products to maintain its leading position in the industry, the R&D expenses increased by approximately 25.3% to approximately
- G-iliac™ Iliac Artery Bifurcation Stent Graft System, LAnavi™ Jointed Steerable Introducer, Freepath™Guidance System and OKcurve™ Steerable Delivery System obtained official registration approval from the China NMPA;
- Xuper™ Open Surgery Stent Graft System obtained the CE certification in EU;
- IBS Angel™ Iron Bioresorbable Scaffold System ("IBS Angel™") obtained registration approval from
Medical Device Authority inMalaysia ; - Artery Stent Graft System (chimney graft) was approved as an innovative medical device in
China ; - Cinenses™ Lung Volume Reduction Reverser System has completed the enrollment of clinical trials in
Europe ; - G-Branch™Thoraco-Abdominal Aortic Stent Graft System has completed the enrollment of FIM study and the mid-term follow-up results are positive;
- LAmbre™ LAA Occluder System, IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System and IBS Angel™ were approved in
the United States by the FDA for "Compassionate Use", and - IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System obtained the implied permission for conducting confirmatory clinical trials in
China .
Meanwhile, the total of 1,350 patent applications have been filed, of which 496 patents have been registered as at
View original content:https://www.prnewswire.com/news-releases/lifetech-scientific-corporation-announces-2021-interim-results-301365365.html
SOURCE
© Canada Newswire, source